Melissa Harris, B.Sc, PharmD.
Development Team lead for Fibrosis
Cardiovascular, Fibrosis & Immunoscience
Melissa Harris is the Development Team lead for Fibrosis, accountable for heading up the creation of strategy for liver and lung fibrosis programs. Prior to this, she served as head of Medical for early stage assets in cardiovascular, fibrosis, and immunoscience. In that role, Melissa built and led a high-performing team of medical specialists who played a pivotal role in ensuring that expert insights from academia, consortia, and our clinical collaboration partners were incorporated into our understanding of early stage assets and development planning. Melissa is recognized as a strong leader and collaborator across the Discovery, Development, and Commercial teams. Melissa obtained her Bachelors of Science and PharmD degree from Rutgers University College of Pharmacy in New Jersey.
Interests and Expertise
Melissa began her career as a hospital pharmacist. She joined Bristol Myers Squibb as a Medical Affairs specialist where she assumed increasing leadership responsibility delivering strategic direction to launches in HIV, hepatitis and immunoscience. As U.S. medical lead she helped to launch Baraclude and later, as a Worldwide Medical Lead, she was accountable for the global launch of the Hepatitis C franchise, including Daklinza and Sunvepra. In addition, she has led the non-registrational data generation capability, spanning the therapeutic areas of cardiovascular, immunoscience, transplant and virology, delivering on data generation strategy through support of investigator-sponsored research, health economics and outcomes research and company-sponsored Phase 3b and Phase 4 programs.
Working Together to Advance Research in Liver Disease
Bristol-Myers Squibb’s research in liver disease began more than 15 years ago, paving the way for a new era in viral hepatitis treatment.
Developing Talent through Experience: The Bristol-Myers Squibb PharmD Program
Bristol-Myers Squibb is dedicated to helping PharmD candidates learn more about the opportunities before them through its nationally recognized PharmD Fellowship and Residency Program.
Bristol-Myers Squibb: Furthering Research in Liver Fibrosis
Tom Lynch, Melissa Harris and Edgar Charles as they discuss Bristol-Myers Squibb’s perspective on the future of liver fibrosis research and commitment to addressing ongoing unmet need during the American Association for the Study of Liver Diseases (AASLD)’s The Liver Meeting